8-K: InMed Reports FY25 Results, Advances Alzheimer's Drug

InMed Pharmaceuticals announced its fiscal year 2025 financial results and provided updates on its Alzheimer's and dry AMD drug development programs, alongside BayMedica's revenue growth.

Summary

• Reported a net loss of $8.2 million for the fiscal year ended June 30, 2025, an increase from $7.7 million in the prior year.
• Cash, cash equivalents, and short-term investments totaled $11.1 million as of June 30, 2025, expected to fund operations into the fourth quarter of calendar year 2026.
• Advanced INM-901 program for Alzheimer's disease, demonstrating statistically significant reductions in neuroinflammation and improvements in cognitive function in preclinical studies.
• Confirmed oral administration for INM-901 achieves therapeutic brain levels comparable to injection.
• Expanded intellectual property for INM-901 with an international patent application.
• Continued preclinical development of INM-089 for dry Age-related Macular Degeneration, showing functional and pathological improvements and selecting an intravitreal formulation.
• BayMedica, the commercial subsidiary, achieved $4.9 million in sales, an 8% increase over the previous fiscal year.
• Research and development expenses decreased to $2.9 million from $3.2 million, but are expected to increase significantly in future periods.
• General and administrative expenses increased to $6.6 million from $5.8 million, primarily due to higher legal and consulting fees.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to strong preclinical data for INM-901, a solid cash runway extending into late 2026, and revenue growth from BayMedica. However, the increased net loss and general & administrative expenses, coupled with the early stage of drug development, temper overall enthusiasm.

Positives

• Cash, cash equivalents, and short-term investments of $11.1 million provide funding into the fourth quarter of calendar year 2026.
• INM-901 for Alzheimer's disease showed statistically significant reductions in neuroinflammation and improvements in cognitive function in preclinical studies.
• Oral administration of INM-901 was confirmed to achieve therapeutic brain levels, offering a significant advantage.
• Expanded intellectual property for INM-901 with a new international patent application.
• INM-089 for dry AMD continues to advance in preclinical studies with demonstrated functional and pathological improvements.
• BayMedica subsidiary achieved sustained revenue growth, reaching $4.9 million, an 8% increase year-over-year.

Negatives

• Net loss increased to $8.2 million for fiscal year 2025, up from $7.7 million in the prior year.
• General and administrative expenses increased to $6.6 million from $5.8 million, driven by higher legal and consulting fees.
• Research and development expenses are expected to increase significantly in future periods, which will likely impact profitability.

Risks

• Actual results, performance, or achievements could be materially different from forward-looking information due to known and unknown risk factors.
• The sufficiency of cash to fund operations into Q4 2026 depends on the level and timing of BayMedica revenues and the Company's operating expenses.

Future Outlook

The company expects to advance its INM-901 Alzheimer's program in fiscal 2026 by developing Chemistry, Manufacturing, and Controls (CMC) activities, preparing for a pre-IND meeting, and conducting GLP-enabling studies to support an Investigational New Drug (IND) submission. Research and development expenses are anticipated to increase significantly in future periods as the pharmaceutical pipeline progresses. Current cash reserves are projected to fund planned operating expenses and capital expenditures into the fourth quarter of calendar year 2026.

Management Comments

• Throughout fiscal 2025, InMed continued to advance its pharmaceutical pipeline, in particular showcasing INM-901's potential as a small-molecule drug candidate that addresses Alzheimer's disease across several interrelated biological pathways rather than relying on a single mechanism.
• We are encouraged by the growing body of neuroinflammation data with INM-901. Across various studies, INM-901 has demonstrated statistically significant reductions in key neuroinflammation signals that are widely implicated in Alzheimer's pathology and may operate independently of amyloid or tau.
• Looking ahead, we remain focused on advancing IND-enabling studies and generating additional data that underscore INM-901's differentiated approach.
• The emphasis on neuroinflammation and multi-pathway approaches appears well aligned with the themes emerging from the recent Alzheimer's Association International Conference (AAIC), where leading researchers highlighted the need to move beyond amyloid and tau pathologies alone.
• InMed has significantly strengthened its balance sheet, positioning the Company to advance its pharmaceutical development programs and deliver on key milestones into the fourth quarter of calendar year 2026.

Industry Context

The company's focus on neuroinflammation and multi-pathway approaches for Alzheimer's disease aligns with emerging industry trends highlighted at the Alzheimer's Association International Conference (AAIC), which suggests a shift beyond traditional amyloid and tau pathologies. This strategic alignment positions the company to potentially contribute to the next generation of Alzheimer's treatments, differentiating its approach from many current therapies.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• **Shareholders**: Increased net loss and G&A expenses could be a concern, but the extended cash runway and promising preclinical data for pipeline assets offer future potential. Capital raises indicate dilution but also funding for development.
• **Patients (Alzheimer's/AMD)**: Continued advancement of INM-901 and INM-089 offers hope for new treatment options for diseases with high unmet medical needs.
• **Employees**: Continued progress in drug development programs and a stable cash position support ongoing operations and employment.
• **Customers (BayMedica)**: Sustained revenue growth in the rare cannabinoids segment indicates continued market demand and product availability.

Next Steps

• Advance Chemistry, Manufacturing, and Controls (CMC) activities for INM-901.
• Prepare for a pre-Investigational New Drug (IND) meeting for INM-901.
• Conduct GLP-enabling studies to support an IND submission for INM-901.

Key Dates

Recommendation

While the company reported an increased net loss and higher G&A expenses, these are somewhat offset by the significant progress in its pharmaceutical pipeline, particularly the promising preclinical data for INM-901 in Alzheimer's disease and the extended cash runway into late 2026. The revenue growth from BayMedica also provides a commercial base. However, the drug candidates are still in early preclinical stages, and significant R&D expenses are anticipated, indicating high future risk. A 'hold' recommendation reflects the balance between the long-term potential of its pipeline and the inherent risks and current financial losses typical of early-stage biotech companies.

Keywords

InMed Pharmaceuticals, Alzheimer's disease, INM-901, neuroinflammation, Age-related Macular Degeneration, INM-089, BayMedica, rare cannabinoids, pharmaceutical development, biotechnology, drug discovery, SEC filing, financial results